Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research. Its lead product is ESKATA, a hydrogen peroxide topical solution that has completed Phase III clinical trials for the treatment of raised seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101, a hydrogen peroxide topical solution, which has completed Phase II clinical trials for the treatment of common warts. In addition, it is developing JAK inhibitors, including ATI-501, which is in Phase II clinical trials for the oral treatment of alopecia totalis and alopecia universalis; and ATI-502 that is in Phase II clinical trials for the topical treatment of patchy autoimmune dermatologic condition, vitiligo, androgenetic alopecia, and loss of eyebrow hair. Further, the company provides contract research services, such as laboratory services under contract research arrangements to pharmaceutical and biotech companies; and discovers and develops kinase inhibitors to treat inflammatory and immunological disorders and cancer. It has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Wayne, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone484-324-7933
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.68 million
Profitability
Miscellaneous
Employees96
OptionableOptionable
Aclaris Therapeutics (NASDAQ:ACRS) Frequently Asked Questions
What is Aclaris Therapeutics' stock symbol?
Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."
How were Aclaris Therapeutics' earnings last quarter?
Aclaris Therapeutics Inc (NASDAQ:ACRS) released its quarterly earnings data on Tuesday, November, 6th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.25) by $0.19. The biotechnology company earned $1.63 million during the quarter, compared to analyst estimates of $1.58 million. Aclaris Therapeutics had a negative net margin of 1,578.24% and a negative return on equity of 63.74%. View Aclaris Therapeutics' Earnings History.
When is Aclaris Therapeutics' next earnings date?
What price target have analysts set for ACRS?
4 Wall Street analysts have issued 1 year price targets for Aclaris Therapeutics' shares. Their predictions range from $34.00 to $53.00. On average, they expect Aclaris Therapeutics' share price to reach $47.25 in the next twelve months. This suggests a possible upside of 642.9% from the stock's current price. View Analyst Price Targets for Aclaris Therapeutics.
What is the consensus analysts' recommendation for Aclaris Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aclaris Therapeutics.
What are Wall Street analysts saying about Aclaris Therapeutics stock?
Here are some recent quotes from research analysts about Aclaris Therapeutics stock:
- 1. According to Zacks Investment Research, "Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. " (1/8/2019)
- 2. Cantor Fitzgerald analysts commented, ": Post a solid quarter of execution, and ahead of what we expect to be important positive catalysts for the company, we are reiterating our OW rating and 12-month PT of $50 for ACRS shares. We expect upward earnings revisions to levels not yet reflected in sell-side consensus expectations to drive the stock higher. This could come from the commercialization and/or advancement of each of ACRS’s key assets. These are: 1) An acceleration in the uptake of Eskata for SK and Rhofade for rosacea, 2) A-101 Phase 3 data for warts, 3) ATI-501 and ATI-502 data releases throughout 2018 and 2019, and, 4) The advancement of ATI-450." (11/6/2018)
Has Aclaris Therapeutics been receiving favorable news coverage?
Press coverage about ACRS stock has been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aclaris Therapeutics earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the stock's share price in the immediate future.
Who are some of Aclaris Therapeutics' key competitors?
Some companies that are related to Aclaris Therapeutics include Amphastar Pharmaceuticals (AMPH), Rhythm Pharmaceuticals (RYTM), Puma Biotechnology (PBYI), Deciphera Pharmaceuticals (DCPH), Tricida (TCDA), Retrophin (RTRX), Homology Medicines (FIXX), Alder Biopharmaceuticals (ALDR), Apellis Pharmaceuticals (APLS), Lexicon Pharmaceuticals (LXRX), Inflarx (IFRX), Athenex (ATNX), Y-mAbs Therapeutics (YMAB), Principia Biopharma (PRNB) and Dynavax Technologies (DVAX).
Who are Aclaris Therapeutics' key executives?
Aclaris Therapeutics' management team includes the folowing people:
- Dr. Neal Walker D.O., Co-Founder, CEO, Pres & Director (Age 48)
- Mr. Christopher V. Powala, Co-Founder and Chief Regulatory & Devel. Officer (Age 59)
- Dr. Stuart D. Shanler, Co-Founder & Chief Scientific Officer (Age 57)
- Mr. Frank Ruffo, Co-Founder & CFO (Age 52)
- Ms. Kamil Ali-Jackson J.D., Co-Founder, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 59)
How do I buy shares of Aclaris Therapeutics?
Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aclaris Therapeutics' stock price today?
One share of ACRS stock can currently be purchased for approximately $6.36.
How big of a company is Aclaris Therapeutics?
Aclaris Therapeutics has a market capitalization of $254.62 million and generates $1.68 million in revenue each year. The biotechnology company earns $-68,520,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis. Aclaris Therapeutics employs 96 workers across the globe.
What is Aclaris Therapeutics' official website?
How can I contact Aclaris Therapeutics?
Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected]
MarketBeat Community Rating for Aclaris Therapeutics (NASDAQ ACRS)
MarketBeat's community ratings are surveys of what our community members think about Aclaris Therapeutics and other stocks. Vote "Outperform" if you believe ACRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
